Pharmaceuticals

Cingulate

Cingulate released FY2026 Q1 earnings on May 14 (EST), actual revenue USD 0 (forecast USD 0), actual EPS USD -0.9523 (forecast USD -0.52)

Cingulate released FY2025 Q4 earnings on March 18 (EST), actual revenue USD 0 (forecast USD 0), actual EPS USD -0.9315 (forecast USD -1.424)

Cingulate released FY2025 annual earnings on March 18 (EST), actual revenue USD 0 (forecast USD 0), actual EPS USD -4.4408 (forecast USD -10.288)

Wall St Analyst Reiterates Buy Rating on Cingulate

Cingulate released FY2025 9 Months earnings on November 13, 2025 (EST), actual revenue USD 0, actual EPS USD -3.499

Cingulate released FY2025 Q3 earnings on November 13 (EST), actual revenue USD 0 (forecast USD 0), actual EPS USD -1.5014 (forecast USD -0.7716)

Cingulate Inc's ADHD Treatment Drug Accepted by FDA

Stonegate Capital Partners Updates Cingulate Inc.'s Drug Development Progress

Cingulate released FY2025 Semi-Annual earnings on August 19, 2025 (EST), with actual revenue of USD 0 and EPS of USD -2.1505

Cingulate released FY2025 Q2 earnings on August 19 (EST), actual revenue USD 0 (forecast USD 0), actual EPS USD -1.2515 (forecast USD -0.8683)

Stonegate Capital Partners Begins Coverage of Cingulate Inc. and Highlights ADHD Drug Progress

Ascendiant Capital Maintains Cingulate's Rating with Slight Price Target Increase

Roth Capital Maintains Buy Rating on Cingulate and Lowers Price Target

Cingulate Receives FDA Pre-NDAs for ADHD Drug CTx-1301

Cingulate released FY2025 Q1 earnings on May 8 (EST), actual revenue USD 0 (forecast USD 0), actual EPS USD -1.0564 (forecast USD -0.9933)

Ascendiant Capital Maintains Cingulate's Rating

Cingulate Inc Completes Pre-NDA Meeting with FDA Discussing ADHD Drug CTX-1301

Cingulate released FY2024 Q4 earnings on March 26 (EST), actual revenue 0 USD (forecast 0 USD), actual EPS -1.8633 USD (forecast -1.375 USD)

Cingulate released FY2024 earnings on March 26 (EST), actual revenue USD 0 (forecast USD 0), actual EPS USD -10.8602 (forecast USD -9.435)

Maxim Group Upgrades Cingulate Rating to Buy

Freecast

Cuprina

U-BX Tech

HORIZON SPACE ACQUISITION II CORP COM USD0.0001 30/03/2026(SUB/RIGHTS)

Defiance Pure Space Dly 2X Strat ETF

VS MEDIA

Everbright Digital

Park Ha Biological Tech

Friedman Industries

Defiance Daily Target 2X Short ASTS ETF

NAVN

CLSK

CING

Wall Street analysts updated price targets for several stocks. BTIG raised Oncology Institute's target to $8, while Piper Sandler kept a Neutral rating. JP Morgan increased Victoria's Secret's target to $88 and lowered Insmed's to $179. DA Davidson cut Guidewire Software's target to $222. Chardan Capital raised CleanSpark's target to $19 but cut Hyperion DeFi's to $7.30. Rosenblatt raised Navan's target to $24, Needham raised Sportradar's to $23, and Ascendiant cut Plus Therapeutics' and Cingulate's targets.

benzinga_article

Navan

Oncology Institute

CleanSpark

Plus Therapeutics

Hyperion DeFi

Guidewire Software

Victorias Secret

Sportradar Group AG

Insmed

Tradr 2X Long CLSK Daily ETF

Oncology Institute - CW22

CLEANSPARK INC C/WTS 29/12/2028 (TO PUR COM)

CINGULATE INC C/WTS 10/12/2026 (TO PUR COM)

Oncology Institute To Rally Over 64%? Here Are 10 Top Analyst Forecasts For Monday

FULC

KMDA

DRTS

MSFT

This week, the biotech sector saw FDA approvals for Philips' AI ultrasound and Lupin's oncology/ophthalmology drugs, while Kamada gained approval for a rabies testing lab. Fulcrum halted its sickle cell program due to malignancy risks, and Cingulate received an FDA complete response letter for its ADHD drug. Key deals included ResMed acquiring Noctrix Health, Mayo Clinic partnering with Microsoft on healthcare AI, and Alpha Tau collaborating with Tolmar for prostate cancer therapy.

- This week, the U.S. biotech sector experienced significant regulatory activity, including FDA approvals for several therapies, study halts, and strategic collaborations.  
- Notable approvals included Philips' Elevate Plus for ultrasound and Lupin's dual FDA approvals in oncology, while Fulcrum Therapeutics halted its Pociredir program due to safety concerns.  
- Positive clinical trial data was reported across various cancer treatments, demonstrating advancements and potential in key therapeutic areas.

rttnews

NOVARTIS AG

Fulcrum Therapeutics

Resmed Inc CHESS Depositary Interests on a ratio of 10 CDIs per ord.sh

Kamada

Koninklijke Philips Elect

Resmed

Alpha Tau Medical

Microsoft

Telix Pharmaceuticals Ltd.

Telix Pharmaceuticals

United Imaging Healthcare

Bluejay Diagnostics

Koninklijke Philips N.V.

ALPHA TAU MEDICAL LTD C/WTS (TO PUR COM)

Weekly Buzz: PHG, KMDA Win FDA Nod; FULC Halts Pociredir; RMD Closes Noctrix Deal; NVS Paces In IgAN

Stonegate Capital Partners Updates Coverage on Cingulate Inc. (CING) 1Q26 | CING Stock News

StockTitan

Stonegate Capital Partners Updates Coverage on Cingulate Inc. (CING) 1Q26 | CING Stock News

MMED

ABVX

Top biotech gainers included ABVX (+24.3%), driven by positive Phase 3 ulcerative colitis trial results for Obefazimod; CING (+21.1%), rising on plans to resubmit an NDA for ADHD therapy after FDA cited manufacturing issues; DRTS (+18.5%), surging following a strategic partnership with Tolmar for Alpha DaRT prostate cancer therapy; and MMED (+15.9%), jumping on strong fiscal year financial results.

MiniMed

Abivax SA

Rezolute

Top Biotech Gainers: ABVX, CING, DRTS, MMED...

LEGN

BJDX

Top biotech gainers included Bluejay Diagnostics (BJDX), which surged 100% on a strategic partnership with Argonaut and a $23.6M private placement; Picard Medical (PMI), up 60% after successful animal studies for its next-gen Emperor Total Artificial Heart; Legend Biotech (LEGN), rising 42% on promising Phase 1 data for LB2501 and LB2102; Cue Biopharma (CUE), up nearly 19% due to board transitions; and Cingulate (CING), gaining 11% despite an FDA CRL for CTx-1301, as the company plans to address manufacturing issues.

nasdaq

Picard Medical

Cue BioPharma

Legend Biotech

Top Biotech Gainers: PMI Advances Artificial Heart, CUE Makes Board Changes, CING Up Despite CRL

The FDA accepted a new drug application for giredestrant, an oral SERD for breast cancer, granting priority review with a PDUFA date of Nov 30, 2026. Conversely, the FDA issued a complete response letter for Cingulate's CTx-1301 ADHD treatment due to manufacturing issues, though clinical safety remains unchallenged. Additionally, former FDA Chief Counsel Dan Troy discussed legal and structural hurdles facing stricter oversight of direct-to-consumer prescription drug advertising.

Pharmexec

<![CDATA[Pharmaceutical Executive Daily: FDA Sends Complete Response Letter for Cingulate's CTx-1301]]>

Cingulate(CING.US)

Oncology Institute To Rally Over 64%? Here Are 10 Top Analyst Forecasts For Monday

Weekly Buzz: PHG, KMDA Win FDA Nod; FULC Halts Pociredir; RMD Closes Noctrix Deal; NVS Paces In IgAN

Stonegate Capital Partners Updates Coverage on Cingulate Inc. (CING) 1Q26 | CING Stock News

Top Biotech Gainers: ABVX, CING, DRTS, MMED...

Top Biotech Gainers: PMI Advances Artificial Heart, CUE Makes Board Changes, CING Up Despite CRL

<![CDATA[Pharmaceutical Executive Daily: FDA Sends Complete Response Letter for Cingulate's CTx-1301]]>